Oncternal Therapeutics discontinues its Phase 1/2 trial of ONCT-808, a CAR-T therapy targeting ROR1, for relapsed/refractory aggressive B-cell lymphoma due to strategic considerations.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.